No black box warning on record for Mometasone Furoate

As of the latest FDA labeling reviewed, Mometasone Furoate (MOMETASONE FUROATE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Mometasone Furoate medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment, Cushing’s syndrome, and hyperglycemia may occur due to systemic absorption. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. Modify use shoul

No black box warning on record for Mometasone Furoate

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment, Cushing’s syndrome, and hyperglycemia may occur due to systemic absorption. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. Modify use shoul

Mometasone Furoate Black Box Warning

No black box warning on record for Mometasone Furoate

Other warnings & precautions

Mometasone Furoate Black Box Warning

No black box warning on record for Mometasone Furoate

Other warnings & precautions